Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis

Efficacy of Valganciclovir Plus Cytomegalovirus Immune Globulin for Prevention of Cytomegalovirus Disease in High-Risk Renal Transplant Recipients

(2014) Angela Q. Maldonado et al.   ANNALS OF PHARMACOTHERAPY

Cytomegalovirus in Solid Organ Transplantation

(2013) R. R. Razonable et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Electronic Estimations of Renal Function Are Inaccurate in Solid-Organ Transplant Recipients and Can Result in Significant Underdosing of Prophylactic Valganciclovir

(2013) J. Trevillyan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation

(2013) M.A. Posadas Salas et al.   Transplant Infectious Disease

Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment

(2012) Elena Beam et al.   Current Infectious Disease Reports

Impact of Cytomegalovirus Disease in D+/R- Kidney Transplant Patients Receiving 6 Months Low-Dose Valganciclovir Prophylaxis

(2011) F. L. Luan et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Comparative Evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) Study Equation for Drug Dosing: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy

(2011) Heather A Nyman et al.   PHARMACOTHERAPY

The risk of cytomegalovirus recurrence after kidney transplantation

(2011) Ilkka Helanterä et al.   TRANSPLANT INTERNATIONAL

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

(2010) A. Humar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Effectiveness of Valganciclovir 900 mg versus 450 mg for Cytomegalovirus Prophylaxis in Transplantation: Direct and Indirect Treatment Comparison Meta-analysis

(2010) A. C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study

(2010) Oriol Manuel et al.   CLINICAL TRANSPLANTATION

New Developments in the Management of Cytomegalovirus Infection after Solid Organ Transplantation

(2010) Albert J. Eid et al.   DRUGS

Defining the Risks for Cytomegalovirus Infection and Disease After Solid Organ Transplantation

(2010) Robert J Stratta et al.   PHARMACOTHERAPY

Direct and indirect effects of cytomegalovirus: can we prevent them?

(2009) Raymund Razonable   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Six-Month Prophylaxis Is Cost Effective in Transplant Patients at High Risk for Cytomegalovirus Infection

(2009) F. L. Luan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Prevention of Cytomegalovirus Disease in Renal Transplantation: Single-Center Experience

(2009) L. Parreira et al.   TRANSPLANTATION PROCEEDINGS

Pharmacokinetics of Low and Maintenance Dose Valganciclovir in Kidney Transplant Recipients

(2008) C. E. Chamberlain et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions

(2008) K. Solez et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation

(2008) Yafit Partouche Avidan et al.   JOURNAL OF INFECTION